ExThera Medical Corporation

ExThera Medical Corporation focuses on innovative medical technologies to address critical health challenges, especially in treating severe COVID-19 infections through advanced hemoperfusion solutions. Founded in 2008, ExThera Medical Corporation is based in Martinez, California, US and specializes in medical technologies. The company raised USD 15. 3 mn in Series B funding on April 26, 2016, led by Fresenius Medical Care Ventures with participation from Fraser Finance and NaHCO3.

The firm has conducted a total of 3 deals so far. Robert Ward serves as the CEO of the company. ExThera Medical specializes in innovative medical technologies aimed at addressing critical health challenges, particularly in the treatment of severe COVID-19 infections. Their flagship product, the Seraph® 100 Microbind® Affinity Blood Filter, utilizes advanced hemoperfusion technology that employs microbead adsorption media chemically bonded with modified heparin.

This design effectively mimics the binding sites that the COVID-19 pathogen utilizes to invade the bloodstream, allowing for the rapid removal of the virus from circulating blood. The Seraph 100 is positioned to serve healthcare providers and institutions engaged in critical care, including hospitals and specialized treatment centers. The product has been authorized for emergency use by the FDA and is primarily marketed within the United States; however, the company is also exploring opportunities in international markets. ExThera Medical's revenue generation is primarily centered around the sales of its Seraph 100 device, which is distributed under an Emergency Use Authorization.

The company engages in direct sales to healthcare facilities, ensuring that their products reach critical care teams who require advanced solutions for treating severe infections. Transactions typically involve healthcare providers purchasing the Seraph 100 on a per-unit basis, aligning with their immediate patient care needs. While specific pricing plans for the Seraph 100 are not disclosed, the transaction structure is expected to reflect a straightforward B2B model where hospitals and healthcare systems acquire devices as part of their procurement processes. This model supports the company’s focus on building strong relationships with medical professionals and institutions dedicated to tackling urgent healthcare challenges.

ExThera Medical Corporation plans to utilize the recent Series B funding of USD 15. 3 mn, raised in June 2016, to support its growth strategy, which includes developing new products and expanding into international markets. The company is focused on enhancing its Seraph 100 device lineup and exploring opportunities in Europe and Asia by 2025. This strategic expansion aims to tap into growing healthcare markets that are increasingly in need of advanced medical solutions for critical care.